基本信息
浏览量:7
职业迁徙
个人简介
Prof Lipman is the author of over 550 peer reviewed publications, 30 book chapters and has been invited to deliver over 120 lectures at national and international conferences in many countries across the world. His research interests include all aspects of infection management in intensive care and he has a special interest in the pharmacokinetics of antibiotic dosage, an area in which he received his MD in 2006. His research into antibiotic usage in acute situations has received international recognition and he is regarded as an expert in the field. As such, he and his research team have conducted and presently conduct a number of clinical trials in Australia, New Zealand, Hong Kong, Europe and the UK.
Prof Lipman is an Editorial Board member for 10 International Journals, is Section Editor on four Antibiotic related Journals, reviews for 23 journals and is an external reviewer for NHMRC project grants (Local) as well as equivalent for a number overseas countries.
He is Chief Investigator on a 7000 patient International Randomised Controlled Trial comparing bolus dosing versus continuous infusions of meropenem and piperacillin-tazobactam
My research has been instrumental in changing antibiotic prescribing habits worldwide for critically ill patients, first with aminoglycosides (I did the first and still largest clinical trial to show single daily dosing to be effective) and more recently with beta-lactam antibiotics. Due to critically ill patients having altered pharmacokinetics, using standard antibiotic dosing for these patients is fraught with problems. This has led to the use of Therapeutic Drug Monitoring (TDM) for beta-lactams.
Prof Lipman is an Editorial Board member for 10 International Journals, is Section Editor on four Antibiotic related Journals, reviews for 23 journals and is an external reviewer for NHMRC project grants (Local) as well as equivalent for a number overseas countries.
He is Chief Investigator on a 7000 patient International Randomised Controlled Trial comparing bolus dosing versus continuous infusions of meropenem and piperacillin-tazobactam
My research has been instrumental in changing antibiotic prescribing habits worldwide for critically ill patients, first with aminoglycosides (I did the first and still largest clinical trial to show single daily dosing to be effective) and more recently with beta-lactam antibiotics. Due to critically ill patients having altered pharmacokinetics, using standard antibiotic dosing for these patients is fraught with problems. This has led to the use of Therapeutic Drug Monitoring (TDM) for beta-lactams.
研究兴趣
论文共 709 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Elin Helset,Vesa Cheng,Hilde Sporsem,Christian Thorstensen,Ingvild Nordøy,Karianne Wiger Gammelsrud, Gorm Hanssen, Erica Ponzi,Jeffrey Lipman, Elisabeth von der Lippe
Acta Anaesthesiologica Scandinavicano. 4 (2024): 502-511
MICROBIOLOGY SPECTRUMno. 2 (2024): e0306523-e0306523
Claire Roger, Lowel Ling, Mélissa Petrier,Loubna Elotmani, Enora Atchade,Bernard Allaouchiche,Frédéric Aubrun,Jean-Michel Constantin, Claire Dahyot-Fizelier,Nathalie Delhaye,Hervé Dupont,Marc-Olivier Fischer,
Annals of General Psychiatryno. 1 (2024): 1-16
Ming G. Chai, Quyen Tu, Menino O. Cotta,Michelle J. Bauer,Ross Balch, Charles Okafor,Tracy Comans,Peter Kruger,Jason Meyer,Kiran Shekar,Kara Brady,Cheryl Fourie,
Intensive Care Medicinepp.1-1, (2024)
Journal of Intensive Medicineno. 1 (2024): 81-93
Elin Helset,Vesa Cheng, Hilde Sporsem,Christian Thorstensen,Ingvild Nordoy,Karianne Wiger Gammelsrud, Gorm Hanssen, Erica Ponzi,Jeffrey Lipman, Elisabeth von Der Lippe
ACTA ANAESTHESIOLOGICA SCANDINAVICAno. 4 (2024): 502-511
Kerina J Denny,Rodney A Lea, Ross Lindell-Innes,Larisa M Haupt,Aaron J Heffernan,Nicholas R Harvey,Oliver Hughes, Van T Cao,Janine Stuart,David L Paterson,John F McNamara,Jacobus P J Ungerer,
Journal of critical care (2023): 154286-154286
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn